Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

D. Von Hoff, Daniel; J. Ervin, Thomas; P. Arena, Francis; Gabriela Chiorean, E.; R. Infante, Jeffrey; J. Moore, Malcolm; E. Seay, Thomas; Tjulandin, Sergei; Wee, Wen; N. Saleh, Mansoor; Harris, Marion; Reni, Michele; Dowden, Scot; A. Laheru, Daniel; Bahary, Nathan; K. Ramanathan, Ramesh; Tabernero, Josep; Hidalgo, Manuel; Goldstein, David; Van Cutsem, Eric; Wei, Xinyu; Iglesias, José; F. Renschler, Markus

doi:10.1056/nejmoa1304369

Public

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Published in New England Journal of Medicine • Oct 16, 2013

Authors:

Daniel D. Von Hoff

Thomas J. Ervin

Francis P. Arena

Abstract

BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients w...

Subject

Gemcitabine

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!